-
NAV$104.44
as of December 26, 2025 -
YTD RETURNS23.11%
as of December 26, 2025 -
Total Net Assets$1.19B
as of December 26, 2025 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
About PPH
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Overview
Why PPH
- Highly Liquid Companies: Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
- Industry Leaders: Index methodology favors the largest companies in the industry
- Global Scope: Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
Performance
Fees
Holdings
Portfolio
Sector Weightings (%) as at 30 Nov 2025
-
Sector
% of Net Assets -
Health Care
99.84 -
Other/Cash
0.16
Country Weightings (%) as at 30 Nov 2025
-
Country
% of Net Assets -
United States
64.82 -
United Kingdom
11.85 -
Switzerland
8.69 -
Denmark
6.04 -
France
4.12 -
Japan
2.25 -
Israel
2.07 -
Other/Cash
0.16